Clinical Trials
12
Active:0
Completed:8
Trial Phases
2 Phases
Phase 3:9
Phase 4:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Phase 3
9 (81.8%)Phase 4
2 (18.2%)Oculusgen (Ologen) Collagen Matrix Implant for Phaco-Trabeculectomy in Primary Glaucoma: A Case-Control Study
Phase 3
- Conditions
- CataractGlaucoma
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2008-06-18
- Lead Sponsor
- Pro Top & Mediking Company Limited
- Target Recruit Count
- 20
- Registration Number
- NCT00687791
- Locations
- 🇸🇬
Singapore Eye Research Institute, Singapore, Singapore
Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery
Phase 4
Completed
- Conditions
- Open Angle Glaucoma
- Interventions
- Drug: Mitomycin-C(MMC) and glaucoma filtering surgeryDevice: Collagen Matrix in Glaucoma Filtering Surgery
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2012-04-25
- Lead Sponsor
- Pro Top & Mediking Company Limited
- Target Recruit Count
- 20
- Registration Number
- NCT00538590
- Locations
- 🇩🇪
Hospital of Universität Köln, Koln, Germany
Oculusgen (Ologen) Glaucoma MMC Control in Estonia
Phase 3
Completed
- Conditions
- Open Angle GlaucomaAngle Closure GlaucomaUveitis GlaucomaYoung Age GlaucomaNeovascular GlaucomaHigh Risk Patient
- Interventions
- Device: ologen (oculusgen) collagen matrix
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- Pro Top & Mediking Company Limited
- Target Recruit Count
- 20
- Registration Number
- NCT00524758
- Locations
- 🇪🇪
Tartu University Clinics, Tartu, Estonia
Ologen(Oculusgen)-Glaucoma and Pterygium Historical Control Study in China Shanghai Sixth People's Hospital
Phase 3
- Conditions
- GlaucomasPterygium
- First Posted Date
- 2007-05-25
- Last Posted Date
- 2011-10-07
- Lead Sponsor
- Pro Top & Mediking Company Limited
- Target Recruit Count
- 60
- Registration Number
- NCT00478790
- Locations
- 🇨🇳
Shanghai sixth People's Hospital, Shanghai, China
Ologen (OculusGen)-Phacotrabeculectomy Historical Control Study in India
Completed
- Conditions
- CataractGlaucoma
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- Pro Top & Mediking Company Limited
- Target Recruit Count
- 10
- Registration Number
- NCT00477685
- Locations
- 🇮🇳
Grewal Eye Institute, Chandigarh, India
- Prev
- 1
- 2
- 3
- Next
News
No news found